Literature DB >> 27373240

Nebenwirkungsmanagement bei Immun-Checkpoint-Blockade durch CTLA-4- und PD1-Antikörper beim metastasierten Melanom.

Katharina C Kähler1, Jessica C Hassel2, Lucie Heinzerling3, Carmen Loquai4, Rotraut Mössner5, Selma Ugurel6, Lisa Zimmer6, Ralf Gutzmer7.   

Abstract

Entities:  

Year:  2016        PMID： 27373240     DOI： 10.1111/ddg.13047_g

Source DB:  PubMed          Journal:  J Dtsch Dermatol Ges        ISSN： 1610-0379            Impact factor:   5.584


× No keyword cloud information.
  5 in total

1.  [Diagnostics of malignant melanoma of the skin : Recommendations of the current S3 guidelines on histology and molecular pathology].

Authors:  C Rose
Journal:  Pathologe       Date:  2017-02       Impact factor: 1.011

Review 2.  [Diagnostics of malignant melanoma of the skin : Recommendations of the current S3 guidelines on histology and molecular pathology].

Authors:  C Rose
Journal:  Hautarzt       Date:  2017-09       Impact factor: 0.751

Review 3.  Cutaneous Side Effects of Targeted Therapy and Immunotherapy for Advanced Melanoma.

Authors:  Irene Russo; Ludovica Zorzetto; Vanna Chiarion Sileni; Mauro Alaibac
Journal:  Scientifica (Cairo)       Date:  2018-12-30

Review 4.  Bacteria-Based Cancer Immunotherapy.

Authors:  Xuehui Huang; Jingmei Pan; Funeng Xu; Binfen Shao; Yi Wang; Xing Guo; Shaobing Zhou
Journal:  Adv Sci (Weinh)       Date:  2021-02-10       Impact factor: 16.806

5.  [Side effects of novel cancer immunotherapies].

Authors:  G S Braun; M Kirschner; A Rübben; R U Wahl; K Amann; K Benesova; J Leipe
Journal:  Nephrologe       Date:  2020-04-29
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.